Smith Chas P & Associates PA Cpas Increases Stake in Novo Nordisk A/S $NVO

Smith Chas P & Associates PA Cpas increased its holdings in Novo Nordisk A/S (NYSE:NVO) by 40.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 570,711 shares of the company’s stock after purchasing an additional 165,286 shares during the period. Novo Nordisk A/S makes up about 1.5% of Smith Chas P & Associates PA Cpas’ holdings, making the stock its 28th biggest holding. Smith Chas P & Associates PA Cpas’ holdings in Novo Nordisk A/S were worth $29,038,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in NVO. Franklin Resources Inc. boosted its position in Novo Nordisk A/S by 4,190.8% during the 3rd quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock valued at $776,016,000 after buying an additional 13,658,867 shares during the period. Capital International Investors boosted its position in Novo Nordisk A/S by 52.4% during the 3rd quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock valued at $982,969,000 after buying an additional 6,092,192 shares during the period. Boston Partners purchased a new stake in Novo Nordisk A/S during the 3rd quarter valued at $310,199,000. Clear Street Group Inc. purchased a new stake in Novo Nordisk A/S during the 3rd quarter valued at $56,378,000. Finally, Armistice Capital LLC purchased a new stake in Novo Nordisk A/S during the 3rd quarter valued at $40,841,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 0.9%

NYSE:NVO opened at $44.59 on Thursday. The company has a 50-day moving average price of $40.67 and a 200-day moving average price of $46.38. Novo Nordisk A/S has a 12 month low of $35.12 and a 12 month high of $81.44. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59. The stock has a market cap of $199.10 billion, a price-to-earnings ratio of 10.47, a P/E/G ratio of 3.94 and a beta of 0.77.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The firm had revenue of $10.85 billion during the quarter. Equities analysts predict that Novo Nordisk A/S will post 3.46 EPS for the current year.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk is being highlighted as one of the more undervalued foreign stocks, with recent results showing a profit beat and a slightly raised full-year outlook, helped by early demand for its Wegovy weight-loss pill in the U.S. Novo Nordisk (NVO) Among Our Most Undervalued Foreign Stocks to Buy Now
• Positive Sentiment: The company announced new cardiometabolic pipeline data, including Phase 3 CagriSema results and additional abstracts for the ADA 2026 meeting, which could strengthen investor confidence in future obesity and diabetes growth drivers. Novo Nordisk advances cardiometabolic pipeline with new data featuring CagriSema and zenagamtide at the American Diabetes Association’s 2026 Scientific Sessions
• Positive Sentiment: Novo Nordisk is nearing EU approval for oral Wegovy, which could expand access, improve convenience, and support longer-term sales growth. Novo Nordisk Nears EU Nod For Oral Wegovy And Investor Opportunity
• Positive Sentiment: Management also launched a share repurchase program, a shareholder-friendly move that can help support the stock. Novo Nordisk A/S – share repurchase programme
• Neutral Sentiment: Several articles compared Novo Nordisk with Eli Lilly and Amgen, keeping attention on GLP-1 competition, pipeline depth, and valuation rather than pointing to any immediate fundamental shock. Novo Nordisk vs. Amgen: Which Pharma Stock Is the Better Buy?
• Negative Sentiment: Brazil approved the first generic copy of Ozempic, signaling new competition in a key growth category and adding pressure to Novo Nordisk’s pricing power. Brazil Clears First Generic Copy of Novo Nordisk’s Ozempic Shot
• Negative Sentiment: Broader healthcare weakness also weighed on the group, with the sector finishing lower in late trading, which may have added short-term pressure to NVO. Sector Update: Healthcare Stocks Decline Late Afternoon

Wall Street Analyst Weigh In

Several brokerages have weighed in on NVO. Zacks Research raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 10th. Wolfe Research began coverage on shares of Novo Nordisk A/S in a research report on Thursday, March 26th. They set a “peer perform” rating for the company. Citigroup reissued a “neutral” rating on shares of Novo Nordisk A/S in a research report on Tuesday, May 12th. BMO Capital Markets reissued a “market perform” rating on shares of Novo Nordisk A/S in a research report on Thursday, February 5th. Finally, Morgan Stanley raised shares of Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 price target for the company in a research report on Tuesday, March 3rd. Four equities research analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $65.56.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.